HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

Wendy B. C. Stevens; Katerina Bakunina; Marloes Cuijpers; Martine Chamuleau; Aart Beeker; Rob Fijnheer; Holger Hebart; Hein P. J. Visser; Jeanette K. Doorduijn; Kim Linton; Martin Dreyling; Daphne de Jong; Marie José Kersten

doi:10.1097/HS9.0000000000000325

HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

Wendy B. C. Stevens^*, Katerina Bakunina, Marloes Cuijpers, Martine Chamuleau, Aart Beeker, Rob Fijnheer, Holger Hebart, Hein P. J. Visser, Jeanette K. Doorduijn, Kim Linton, Martin Dreyling, Daphne de Jong, Marie José Kersten

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Article number	e325
Journal	HemaSphere
Volume	4
Issue number	1
DOIs	https://doi.org/10.1097/HS9.0000000000000325
Publication status	Published - 2020

Access to Document

10.1097/HS9.0000000000000325

Cite this

Stevens, W. B. C., Bakunina, K., Cuijpers, M., Chamuleau, M., Beeker, A., Fijnheer, R., Hebart, H., Visser, H. P. J., Doorduijn, J. K., Linton, K., Dreyling, M., de Jong, D., & Kersten, M. J. (2020). HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma. HemaSphere, 4(1), [e325]. https://doi.org/10.1097/HS9.0000000000000325

@article{97499e0826ef4e47bb102bb3128a195f,

title = "HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma",

author = "Stevens, {Wendy B. C.} and Katerina Bakunina and Marloes Cuijpers and Martine Chamuleau and Aart Beeker and Rob Fijnheer and Holger Hebart and Visser, {Hein P. J.} and Doorduijn, {Jeanette K.} and Kim Linton and Martin Dreyling and {de Jong}, Daphne and Kersten, {Marie Jos{\'e}}",

year = "2020",

doi = "10.1097/HS9.0000000000000325",

language = "English",

volume = "4",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "1",

}

Stevens, WBC, Bakunina, K, Cuijpers, M, Chamuleau, M, Beeker, A, Fijnheer, R, Hebart, H, Visser, HPJ, Doorduijn, JK, Linton, K, Dreyling, M, de Jong, D & Kersten, MJ 2020, 'HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma', HemaSphere, vol. 4, no. 1, e325. https://doi.org/10.1097/HS9.0000000000000325

HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma. / Stevens, Wendy B. C.; Bakunina, Katerina; Cuijpers, Marloes et al.

In: HemaSphere, Vol. 4, No. 1, e325, 2020.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

AU - Stevens, Wendy B. C.

AU - Bakunina, Katerina

AU - Cuijpers, Marloes

AU - Chamuleau, Martine

AU - Beeker, Aart

AU - Fijnheer, Rob

AU - Hebart, Holger

AU - Visser, Hein P. J.

AU - Doorduijn, Jeanette K.

AU - Linton, Kim

AU - Dreyling, Martin

AU - de Jong, Daphne

AU - Kersten, Marie José

PY - 2020

Y1 - 2020

UR - http://www.scopus.com/inward/record.url?scp=85093960763&partnerID=8YFLogxK

U2 - 10.1097/HS9.0000000000000325

DO - 10.1097/HS9.0000000000000325

M3 - Letter

C2 - 32072141

VL - 4

JO - HemaSphere

JF - HemaSphere

SN - 2572-9241

IS - 1

M1 - e325

ER -

HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

Access to Document

Other files and links

Cite this